Add like
Add dislike
Add to saved papers

Tumour endoprosthetic reconstruction for primary aggressive and malignant bone tumours of the distal femur.

UNLABELLED: At the Philippine General Hospital, tumour endoprostheses have become an option for reconstruction after limb saving surgery for primary bone tumors. We performed a retrospective review of patients with primary bone tumors of the distal femur who underwent tumor excision and reconstruction using tumor endoprostheses. Outcome measures included prosthetic survival, functional outcome and complications. Twenty-two patients were evaluated; 14 males and 8 females, with a mean age of 18 years and a mean follow-up of 56 months. The overall 2-year endoprosthetic survival rate was 86%. Mean MSTS was 23/30. There were a total of 6 revisions. Failure modes included 3 infections, 3 aseptic loosening, 4 structural failures, 2 soft tissue failures and 3 tumor progression. Our early results show that tumor endoprosthesis reconstruction is an acceptable option for patients with primary bone tumor of the distal femur. Survival rates, failure modes and functional outcomes are comparable to other reported studies.

KEY WORDS: Supracondylar humerus, K-wire fixation, day care procedure.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app